

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for the Use of ghrelin or an analogue thereof for the preparation of a medicament for one or more of treatment and/or prevention of loss of body weight and body fat and/or prophylaxis or treatment of cachexia, and/or stimulation of appetite and/or stimulation of food intake and/or stimulation of weight gain and/or increasing body fat mass in a gastrectomized individual, comprising administering a therapeutically effective amount of ghrelin or analogue thereof to said individual.

2. (currently amended) The ~~use~~ method according to claim 1, wherein the ghrelin or analogue thereof is a ghrelin-like compound or a pharmaceutically acceptable salt thereof wherein the ghrelin-like compound comprises a structure defined by formula I

$Z^1 - (X^1)_m - (X^2) - (X^3)_n - Z^2$, wherein

Z^1 is an optionally present protecting group
each X^1 is independently selected from an amino acid,
wherein said amino acid is selected from the group
consisting of naturally occurring and synthetic amino acids,
 X^2 is any amino acid selected from the group consisting of
naturally occurring and synthetic occurring amino acids,
said amino acid being modified with a bulky hydrophobic
group, ~~preferably an acyl group, or a fatty acid,~~
each X^3 is independently selected from an amino acid,
wherein said amino acid is selected from the group
consisting of naturally occurring and synthetic amino acids,
wherein one or more of X^1 and X^3 optionally may be modified
by a bulky hydrophobic group, ~~preferably an acyl group, or a~~
~~fatty acid,~~ Z^2 is an optionally present protecting group,
 m is an integer in the range of from 1-10, and/or
 n is 0 or an integer in the range of from 1-35.

3. (currently amended) ~~Use~~ The method according to ~~any of~~
~~the preceding~~ claims 2, wherein m is an integer in the range
of from 1-9, ~~such as of from 1-8, such as of from 1-7, such as~~
~~of from 1-6, such as of from 1-5, such as of from 1-4, such as~~
~~of from 1-3, such as of from 1-2, such as 2,~~

4. (currently amended) ~~Use~~ The method according to ~~any of the preceding~~ claims 2, wherein X^2 is selected from the group consisting of modified Ser, modified Cys and modified Lys, ~~such as wherein X^2 is modified Ser.~~

5. (currently amended) ~~Use~~ The method according to ~~any of the preceding~~ claims 2, wherein the ghrelin-like compound is selected from ~~a compound~~ the group consisting of:

formula II $Z^1 - \text{Gly} - (X^1)_{m-1} - (X^2) - (X^3)_n - Z^2$,

formula III $Z^1 - \text{Gly} - \text{Ser} - (X^2) - (X^3)_n - Z^2$, and

formula IV $Z^1 - \text{Gly} - (X^2) - (X^3)_n - Z^2$.

6. (currently amended) ~~Use~~ The method according to ~~any of the preceding~~ claims 2, wherein the ghrelin-like compound is having formula III.

7. (currently amended) ~~Use~~ The method according to ~~any of the preceding~~ claims 2, wherein $(X^3)_n$ comprises a sequence selected from ~~one or more of the sequences shown below~~ the group consisting of:

:
: In re of: JANSSON7

Phe Leu Ser Pro Glu His Gln (SEQ ID NO: 22)

Phe Leu Ser Pro Glu His (SEQ ID NO: 23)

Phe Leu Ser Pro Glu (SEQ ID NO: 24)

Phe Leu Ser Pro (SEQ ID NO: 25)

Phe Leu Ser (SEQ ID NO: 26)

Phe Leu (SEQ ID NO: 27)

Phe (SEQ ID NO: 28)

8. (currently amended) ~~Use~~ The method according to ~~any of the preceding claims 2,~~ wherein n is an integer in the range of from 1-25., ~~such as of from 1-24, such as from 1-15, such as of from 1-10, such as of from 10-25, such as of from 10-24, such as of from 15-25, such as of from 15-24,~~

9. (currently amended) ~~Use~~ The method according to ~~any of the preceding claims 2,~~ wherein $(X^3)_n$ is selected from the group consisting of~~one or more of the sequences shown below:~~

; In re of: JANSSON7

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg (SEQ ID NO: 4)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys Pro Pro Ala Lys Leu Gln Pro (SEQ ID NO:5)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys Pro Pro Ala Lys Leu Gln (SEQ ID NO: 6)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys Pro Pro Ala Lys Leu (SEQ ID NO: 7)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys Pro Pro Ala Lys (SEQ ID NO: 8)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys Pro Pro Ala (SEQ ID NO: 9)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys Pro Pro (SEQ ID NO: 10)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys Pro (SEQ ID NO: 11)

: In re of: JANSSON7

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys Lys (SEQ ID NO: 12)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
Lys (SEQ ID NO: 13)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser
(SEQ ID NO: 14)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu
(SEQ ID NO: 15)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys (SEQ
ID NO: 16)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg (SEQ ID
NO: 17)

Phe Leu Ser Pro Glu His Gln Arg Val Gln Gln (SEQ ID NO:
18)

Phe Leu Ser Pro Glu His Gln Arg Val Gln (SEQ ID NO: 19)

Phe Leu Ser Pro Glu His Gln Arg Val (SEQ ID NO: 20)

: In re of: JANSSON7

Phe Leu Ser Pro Glu His Gln Arg (SEQ ID NO: 21)

Phe Leu Ser Pro Glu His Gln (SEQ ID NO: 22)

Phe Leu Ser Pro Glu His (SEQ ID NO: 23)

Phe Leu Ser Pro Glu (SEQ ID NO: 24)

Phe Leu Ser Pro (SEQ ID NO: 25)

Phe Leu Ser (SEQ ID NO: 26)

Phe Leu (SEQ ID NO: 27)

Phe (SEQ ID NO: 28)

10. (currently amended) ~~Use~~ The method according to ~~any~~
~~of the preceding~~ claims 2, wherein the bulky hydrophobic acyl
group is selected from a C1-C35 acyl group, ~~such as a C1-~~
~~C20 acyl group, such as a C1-C15 acyl group, such as a C6-~~
~~C15 acyl group, such as a C6-C12 acyl group, such as a C8-~~
~~C12 acyl group.~~

11-13. (cancelled)

14. (currently amended) ~~Use~~ The method according to ~~any~~
~~of the preceding claims 2~~, wherein the ~~medicament comprises a~~
~~solution of the ghrelin-like compound or a salt thereof~~ is
provided in the form of a solution.

15. (currently amended) ~~Use~~ The method ~~Use~~ according to
claim 14, wherein the solvent is saline.

16-17. (cancelled)

18. (currently amended) The ~~use~~ method according to ~~any~~
~~of the preceding claims 1~~, wherein said ghrelin or analogue
thereof is administered in combination with another stomach
derived factor.

19. (cancelled)

20. (currently amended) The ~~use~~ method according to ~~any~~
~~of the preceding claims 1~~, wherein said ghrelin or analogue
thereof is administered in combination with another body
weight and/or body fat inducing factor.

21. (cancelled)

22. (currently amended) The ~~use~~ method according to ~~any~~ ~~of the preceding~~ claims 1, wherein the ~~medicament~~ ghrelin or analogue thereof is provided in a form ~~is~~ suitable for oral, nasal, transdermal, pulmonal, or parenteral administration.

23-26. (cancelled)

27. (currently amended) The method ~~Use~~ according to claim 1, ~~any claims 1-22~~ wherein the ghrelin or analogue thereof is provided in a form suitable for subcutaneous administration ~~medicament is in a formulation for parenteral administration.~~

28. (currently amended) The ~~use~~ method according to ~~any~~ ~~of the preceding~~ claims 1, wherein the ~~active compound~~ ghrelin or analogue thereof is administered in a dose of from about 0.01 µg/kg body weight to 10 mg/kg body weight daily, ~~preferably between 0.1 to 10 µg/kg body weight.~~

29. (cancelled)

30. (currently amended) ~~Use~~ The method according to ~~any~~ ~~of the preceding claims~~ claim 1, wherein the ~~medicament~~

. In re of: JANSSON7

ghrelin or analogue thereof is administered prior to or during
a meal.

31-37. (cancelled)